|  | Baseline pre-intervention | Post-intervention | Follow-up (3 and 6 months after AET intake) |
---|---|---|---|---|
Inclusion criteria | Interview measures | Â | Â | Â |
 | Structured psychiatric interview (mini-dips) | x1 |  |  |
 | Demographic and medical data | x |  |  |
 | Questionnaire measures |  |  |  |
Primary + Secondary Outcomes | Physical symptoms and side effects + coping (GASE+Coping) | x | Â | x |
 | Quality of life (EORTC QLQ C30 & BR23) | x |  | x |
 | Adherence (MARS-D), Adherence Intention | x | x | x |
Expectation Scales | Expected side effects + expected coping (GASE-Expect + * *Coping) | x | x | x |
 | Illness beliefs (IPQ-B) | x | x | x |
 | Beliefs about medicines (BMQ-D) | x | x | x |
Process Variables | Fear of progression (PA-F-K) | x | x | x |
 | Anxiety and depression (HADS) | x | x | x |
 | Knowledge hormone receptor | x | x | x |
 | Treatment evaluation |  | x2 |  |
Control Variables | Somatosensory amplification (SSAS) | x | Â | Â |
 | Prior experiences with endocrine treatment | x |  |  |
 | Partnership quality | x |  |  |
 | Additional medication | x |  | x |